Review



small molecule multitarget drugs lenvatinib  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals small molecule multitarget drugs lenvatinib
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Small Molecule Multitarget Drugs Lenvatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecule multitarget drugs lenvatinib/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    small molecule multitarget drugs lenvatinib - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study"

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    Journal: Liver Cancer

    doi: 10.1159/000545545

    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Figure Legend Snippet: Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.

    Techniques Used:

    Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.
    Figure Legend Snippet: Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.

    Techniques Used:

    Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.
    Figure Legend Snippet: Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.

    Techniques Used:



    Similar Products

    small molecule multitarget drugs lenvatinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals small molecule multitarget drugs lenvatinib
    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the <t>lenvatinib</t> group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.
    Small Molecule Multitarget Drugs Lenvatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecule multitarget drugs lenvatinib/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    small molecule multitarget drugs lenvatinib - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Kaplan-Meier curves of OS and PFS for patients in the different groups. OS ( a ) and PFS ( b ) of patients in the lenvatinib group ( N = 258) or the bevacizumab group ( N = 113) before PSM. OS ( c ) and PFS ( d ) for the lenvatinib group ( N = 152) and the bevacizumab group ( N = 82) after PSM. OS ( e ) and PFS ( f ) for patients in the lenvatinib group ( N = 234) and the bevacizumab group ( N = 237) weighted by IPTW. PSM, propensity score matching; IPTW, inverse probability of treatment weighting.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques:

    Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Swimmer plot of overall survival and treatment duration in lenvatinib and bevacizumab groups.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques:

    Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.

    Journal: Liver Cancer

    Article Title: Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study

    doi: 10.1159/000545545

    Figure Lengend Snippet: Tumor responses rates based on mRECIST in the lenvatinib group and the bevacizumab group before PSM and after PSM.

    Article Snippet: Among small molecule multitarget drugs, lenvatinib has the highest ORR of 18.8% [ ].

    Techniques: